The European Medicines Agency (EMA) has said it is confident that the vaccines currently used in the European Union protect against the variant discovered in.
EMA concludes evaluation of Sputnik V compliance with clinical practice 1 minute read
The Hague, May 12 (EFE).- The European Medicines Agency (EMA) said Wednesday it had concluded its evaluation of good clinical practice in trials for Russian vaccine Sputnik V.
The EU regulator also announced it will closely monitor vaccination campaigns across member states to establish how long the vaccine is effective against Covid-19 and whether a third dose will be necessary.
The EMA’s Head of Clinical Studies and Manufacturing Fergus Sweeney said EU inspectors are now visiting Sputnik V manufacturing sites to verify compliance.
Results from both evaluations will contribute to the final assessment of the Russian vaccine, which could lead to a recommendation to authorize its use in the EU.
Central govt needs to get rid of Its piecemeal vaccine strategy
Premium
A medico administers a dose of Covid-19 vaccine to a woman during the third phase of inoculation drive in Gurugram.
5 min read
Share Via
Read Full Story
A couple of news reports published on Monday suggested that the central government hadn’t placed any orders for covid vaccines lately, with either the Serum Institute or Bharat Biotech.
The government issued a press release denying the same. In the release, the government said it has placed orders for 110 million doses of Covishield with Serum Institute and 50 million doses of Covaxin with Bharat Biotech. It also said that advance payments of ₹1732.5 crore and ₹787.5 crore respectively were given to the two companies on 28 April. These orders were for the months of May, June and July.
Dr Rawiri Taonui Covid Maori | Seven Variants in New Zealand and Low Rate of Maori Vaccination 04 May 2021 05:57 AM Photo Supplied.
More Related Stories
World Summary
The world has delivered more than 1.15 billion vaccines as countries race to inoculate populations against Covid-19. Most vaccinations have been in rich countries.
A 4th Mega-Wave driven by the B117 (Britain), B1351 (South African) and P1 (Brazil) variants is severely affecting the Indian sub-continent, Latin America, parts of Southern, Western and Eastern Europe, the Middle East and Asia. Vaccines are less effective against these strains. Companies such as Pfizer-BioNTech and Moderna, the two most effective vaccines, are preparing vaccine top-ups for delivery at the end of this year or early in 2022 to protect against these variants.
16 Monate Dauerkrise: Wie geht es nach der Pandemie weiter? n-tv.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from n-tv.de Daily Mail and Mail on Sunday newspapers.